Upstream Biosciences Inc. ~ Press Releases

PRESS RELEASE - JULY 16th, 2007

UPSTREAM BIOSCIENCES HIRES GENDELLINDHEIM BIOCOM PARTNERS AS AGENCY OF RECORD
Wall Street-Based PR & IR Boutique Specializes in Supporting Emerging Biotech Leaders

Vancouver, British Columbia– July 16, 2007– Upstream Biosciences Inc. (OTCBB: UPBS), today announced it has hired GendeLLindheim BioCom Partners, LLC, as its communications agency of record. The firm, known as BioCom Partners, is a Manhattan-based public and investor relations boutique that specializes in supporting the growth of emerging and established biotechnology leaders. Principals Stephen Gendel and Barbara Lindheim bring decades of first-hand, professional expertise in media, financial and investor relations to their clients, who range from promising private firms to top-ranked industry bell weather stocks.

“Stephen and Barbara bring a tremendous depth of industry expertise, insight and contacts to our business,” said Joel L. Bellenson, Chief Executive Officer of Upstream. “We believe their counsel will contribute significantly to our success as we advance our biomarker platform toward validation and commercialization.”

Upstream Biosciences discovers and develops diagnostic and prognostic biomarkers. It currently is pursuing biomarkers to assess drug response, as well as for cancers of the liver, prostate, ovaries and thyroid. Upstream’s diagnostics are intended to point the way toward optimal treatments for each patient and to enhance the accuracy of early detection of cancer.

“An advantage of a boutique firm is that we can target our practice to biotech companies such as Upstream that have highly innovative and commercially promising technology,” noted Ms. Lindheim. “We are especially pleased by the opportunity to support Upstream and its novel diagnostic biomarker technology that has the potential to transform the promise of personalized medicine into a reality.”

Founded in 2003, GendeLLindheim BioCom Partners is a full-service life sciences communications boutique distinguished by the hands-on expertise of its principals, its demonstrated ability to help young companies communicate complex technologies clearly and powerfully, and its commitment to delivering top quality professional services at reasonable rates. Stephen Gendel brings clients his knowledge and contacts from 25 years as an award-winning television reporter, including founding the health and science beat at business cable powerhouse CNBC. Barbara Lindheim brings her 15 years of expertise as a biopharmaceutical marketing and communications executive, along with the financial savvy and contacts she acquired along with her Harvard MBA. BioCom Partners is headquartered on Wall Street in New York City.

For more information, please contact Samantha Haynes at 1-800-539-0289 or info@upstreambio.com.

Media Contact: GendeLLindheim BioCom Partners, Barbara Lindheim: Tel: 212- 918-4650

» BACK

About Upstream Biosciences Inc.
Upstream Biosciences Inc. is an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response founded in 2004. Upstream discovers, develops, and licenses genetic based diagnostics for cancer susceptibility and drug response. Upstream's proprietary data mining pipeline enables it to locate and analyze genetic variations in the regions of DNA 'upstream' of the gene, the 'gene switches,' which control the quantities and timing of expression of the genes, and proteins important to disease and drug response.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements”, as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, the expectation and/or claim, as applicable, that: (i) Upstream may become an emerging leader in the field of diagnostics for cancer and the prediction of drug response; (ii) the analysis conducted by Genpathway is intended to provide information to validate Upstream’s first two cancer biomarkers and drug response asssy; (iii) Genpathway will apply its assays to help elucidate critical parameters involving specific gene transcription factors and pathways; (iv) the agreement with Genpathway may allow Upstream to acquire in-depth information that is not available with other analytic methods; and (v) Upstream is developing diagnostic tests designed to aid in the early detection of cancer by identifying individuals with a high degree of susceptibility to the disease and genetic-based diagnostic tests to measure how individuals respond to specific drugs. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others: (i) the risk that Upstream does not execute its business plan; (ii) the inability of Upstream to keep pace with technological advancements in the field of genetic diagnostics; (iii) Upstream’s inability to adequately protect its intellectual property or Upstream’s inadvertent infringement of third party intellectual property; (iv) Upstream not being able to retain key employees; (v) competitors providing better or cheaper products and technologies; (vi) markets for Upstream’s products not developing as expected; (vii) Upstream’s inability to finance its operations or growth; (viii) inability to obtain all necessary government and regulatory approvals; and (ix) the inability to effectively market and commercialize Upstream’s technologies, including the establishment of viable relationships with third parties. These forward-looking statements are made as of the date of this news release and Upstream assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although Upstream believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in Upstream’s periodic reports filed from time-to-time with the Securities and Exchange Commission and available at www.sec.gov.

DISCLAIMER FOR HISTORICAL PRESS RELEASES AND SEC FILINGS
This section contains historical and archived press releases and SEC filings for Upstream Biosciences Inc. The information in these press releases and SEC filings is historical in nature, has not been updated, and is current only to the date indicated in the particular press release or SEC filing. This information may no longer be accurate and therefore you should not rely on the any information contained in these press releases or SEC filings and should refer to our latest press releases and SEC filings. To the extent permitted by law, Upstream Biosciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.